Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.

Pavlos Msaouel,Rebecca Slack-Tidwell,Giannicola Genovese,Najat C. Daw,Arlene Odelia Siefker-Radtke,Nizar M. Tannir

Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.

2019

Pavlos Msaouel
Rebecca Slack-Tidwell
Giannicola Genovese
Najat C. Daw
Arlene Odelia Siefker-Radtke
Nizar M. Tannir

TPS678Background: SMARCB1 (also known as INI-1, hSNF5, or BAF47) is a potent tumor suppressor inactivated in all cases of renal medullary carcinoma (RMC) and renal cell carcinoma unclassified with ...

Keywords:

SMARCB1
Ixazomib
Pathology
Suppressor
Cancer research
Doxorubicin
Renal medullary carcinoma
Renal cell carcinoma
Gemcitabine
Medicine
Kidney

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations